MediciNova Completes Phase 2 MN-001 Trial, Enrolls 100 ALS Patients, Secures Patent
MNOV•MediciNova completed last patient last visit in its Phase 2 MN-001 trial for hypertriglyceridemia and NAFLD in T2DM, with topline data expected in Q3 2026. The company has enrolled 100 of 200 patients in its ALS Expanded-Access SEANOBI study and received a U.S. patent allowance for ibudilast combination therapy expiring no earlier than September 2042.
1. Phase 2 MN-001 Trial Milestone
MediciNova achieved last patient last visit in its multicenter, randomized, double-blind, placebo-controlled Phase 2 MN-001-NATG-202 trial evaluating tipelukast for hypertriglyceridemia and NAFLD in type 2 diabetes patients. Topline data from this study are slated for release in the third quarter of 2026, representing a key catalyst for the company’s late-stage pipeline.
2. ALS SEANOBI Study Progress
Under the SEANOBI expanded-access program (NCT06743776), MediciNova activated 12 U.S. sites and has enrolled 100 of the planned 200 amyotrophic lateral sclerosis patients to evaluate ibudilast. This halfway enrollment milestone underscores advancing patient access and supports the anticipated year-end COMBAT ALS Phase 2b/3 registration trial data.
3. Patent Allowance for Ibudilast Combination
The U.S. Patent and Trademark Office issued a Notice of Allowance covering the use of ibudilast with anti-PD-1 antibodies for glioblastoma treatment. The patent’s claims encompass diverse dosing regimens and administration routes, strengthening MediciNova’s IP position through at least September 2042.
4. Research Coverage Expansion and Outlook
MediciNova’s equity research coverage has grown from one firm to four, including D. Boral Capital, Lucid Capital Markets, H.C. Wainwright & Co. and Maxim Group. Management cites this as validation of its late-stage assets and anticipates continued momentum toward key data readouts and prudent capital management in the second half of 2026.
